Progression of Interstitial Fibrosis and Tubular Atrophy in Low Immunological Risk Renal Transplants Monitored by Sequential Surveillance Biopsies: The Influence of TAC Exposure and Metabolism

Other authors

Institut Català de la Salut

[Chamoun B, Torres IB, Sellarés J, Perelló M, Toapanta NG, Cidraque I] Servei de Nefrologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Gabaldón A, Salcedo M] Servei de Patologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Castellá E, Guri X] Servei de Radiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Moreso F, Seron D] Servei de Nefrologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain

Vall d'Hebron Barcelona Hospital Campus

Publication date

2021-06-29T10:52:39Z

2021-06-29T10:52:39Z

2021-01-04



Abstract

Coeficient de variació; Biòpsies de protocol; Trasplantament renal


Coeficiente de variación; Biopsias de protocolo; Trasplante renal


Coefficient of variation; Protocol biopsies; Renal transplantation


The combination of tacrolimus (TAC) and mycophenolate is the most widely employed maintenance immunosuppression in renal transplants. Different surrogates of tacrolimus exposure or metabolism such as tacrolimus trough levels (TAC-C0), coefficient of variation of tacrolimus (CV-TAC-C0), time in therapeutic range (TTR), and tacrolimus concentration dose ratio (C/D) have been associated with graft outcomes. We explore in a cohort of low immunological risk renal transplants (n = 85) treated with TAC, mycophenolate mofetil (MMF), and steroids and then monitored by paired surveillance biopsies the association between histological lesions and TAC-C0 at the time of biopsy as well as CV-TAC-C0, TTR, and C/D during follow up. Interstitial inflammation (i-Banff score ≥ 1) in the first surveillance biopsy was associated with TAC-C0 (odds ratio (OR): 0.69, 95% confidence interval (CI): 0.50–0.96; p = 0.027). In the second surveillance biopsy, inflammation was associated with time below the therapeutic range (OR: 1.05 and 95% CI: 1.01–1.10; p = 0.023). Interstitial inflammation in scarred areas (i-IFTA score ≥ 1) was not associated with surrogates of TAC exposure/metabolism. Progression of interstitial fibrosis/tubular atrophy (IF/TA) was observed in 35 cases (41.2%). Multivariate regression logistic analysis showed that mean C/D (OR: 0.48; 95% CI: 0.25–0.92; p = 0.026) and IF/TA in the first biopsy (OR: 0.43, 95% CI: 0.24–0.77, p = 0.005) were associated with IF/TA progression between biopsies. A low C/D ratio is associated with IF/TA progression, suggesting that TAC nephrotoxicity may contribute to fibrosis progression in well immunosuppressed patients. Our data support that TAC exposure is associated with inflammation in healthy kidney areas but not in scarred tissue.


The authors received grants from Red de Investigación Renal (REDinREN RD16/0009/0030), Fondo de Investigación Sanitaria del Instituto de Salud Carlos III (PI 18/01704, PI 18/01382), the Spanish Society of Transplantation and a Diaverum Spain restricted grant. Betty Chamoun has been supported by a VHIR (Vall Hebron Institute Research) grant.

Document Type

Article


Published version

Language

English

Publisher

MDPI

Related items

Journal of Clinical Medicine;10(1)

https://www.mdpi.com/2077-0383/10/1/141

info:eu-repo/grantAgreement/ES/PE2013-2016/PI18%2F01704

info:eu-repo/grantAgreement/ES/PE2013-2016/PI18%2F01382

info:eu-repo/grantAgreement/ES/PE2013-2016/RD16%2F0009%2F0030

Recommended citation

This citation was generated automatically.

Rights

Attribution 4.0 International

http://creativecommons.org/licenses/by/4.0/

This item appears in the following Collection(s)